Author

Solène Besson

University of FreiburgORCID 0000-0002-0705-6491Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

Asma Y. AlrawashdehiD· 2 shared Dietrich Alexander RuessiD· 2 shared Dominik von ElverfeldtiD· 2 shared Geoffroy AndrieuxiD· 2 shared Huda Jumaa· 2 shared Melanie BoerriesiD· 2 shared Philipp HafneriD· 2 shared Stefan Fichtner‐FeigliD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Asma Y. AlrawashdehORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Immunomodulatory impact of PTPN11/SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer

Asma Y. Alrawashdeh, Xun Chen, Philipp Hafner, Steffen Johannes Keller, Tonmoy Das, Huda Jumaa, Thomas Yul Avery, Solène Besson, Silke Hempel, Stephanie Mewes, Kerstin Meyer, Mohammad A. Al Shhab, Mara Schneider, Johannes David Lettner, Dominik von Elverfeldt, , Dietrich Alexander Ruess

This study investigates the immunomodulatory effects of SHP2-based vertical RAS pathway inhibition in pancreatic cancer, revealing both immune-activating and suppressive changes that evolve with treatment.

bioRxiv · May 27, 2026 · PreprintImmunology

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Philipp Hafner, Steffen Johannes Keller, Xun Chen, Asma Y. Alrawashdeh, Huda Jumaa, Friederike Inga Nollmann, Solène Besson, Judith Kemming, Oliver Gorka, Tonmoy Das, Bismark Appiah, Ariane Lehmann, Mujia Jenny Li, Petya Apostolova, Bertram Bengsch, , Dietrich Alexander Ruess

This study shows that dual SHP2/MEK inhibition in pancreatic cancer causes mitochondrial changes and ROS elevation, leading to a therapy-resistant state that can be targeted with GPX4 inhibition.

Signal Transduction and Targeted Therapy · Jan 16, 2026Peer-reviewedCancer Biology